type 2 receptors for vascular endothelial growth factor are believed to be involved in the pathophysiology of ovarian hyperstimulation syndrome (ohss). the objective of this study was to examine the preventive effects of cabergoline on ohss and its complications. the study is a non randomized clinical trial conducted in 2006-2008 on 75 patients, which were at risk of ohss and underwent assisted...

We report a combined intra-uterine and tubal pregnancy associated with mild ovarian hyperstimulation syndrome (OHSS) following ovulation induction by clomiphene. The diagnosis of ectopic pregnancy was originally missed until rupture occurred. OHSS confused the clinical picture, the important diagnostic feature being the fall in the haemoglobin concentration. The patient had a left partial salpi...

Background: The affordable protocol to prevent the severe OHSS in two groups of patients PCO syndrome and non PCO high responder. Methods and Materials: PubMed and Medline were searched from January 2000 till end of May 2014. This Study investigates whether the mild protocol is associated to prevent severe OHSS in infertile female. Results: According to this survey, 9 studies were included and ...

Ovarian hyperstimulation syndrome (OHSS) still remains a life-threatening complication of in vitro fertilization treatment (IVF), keeping patients and especially those, who previously experienced OHSS, from attempting infertility treatment and childbearing. The recent implementation of four new modalities: the GnRH antagonist protocol, GnRH agonist (GnRHa) triggering of ovulation, blastocyst tr...

Ovarian hyperstimulation syndrome (OHSS) is one of the major complications in artificial reproductive technology, especially in high responders. Exogenous human chorionic gonadotropin (hCG) for triggering final oocyte maturation during controlled ovarian stimulation (COS) is primarily responsible for the pathogenesis of early-onset OHSS. Several strategies were offered to prevent OHSS, includin...

The Ovarian Hyperstimulation Syndrome (OHSS) represents one of the biggest nightmares of all physicians involved in Assisted Reproductive Technologies (ART). Every year, several hundreds of women are hospitalized and to date several deaths have been reported. The pivotal event in the development of OHSS is the disruption of capillary integrity that results in leakage of intravascular fluid and ...

BACKGROUND We aimed to compare human menopausal gonadotropin (hMG) and recombinant follicle-stimulating hormone (r FSH) with respect to clinical outcomes and the development of ovarian hyperstimulation syndrome (OHSS) for patients with polycystic ovary syndrome (PCOS) treated with in vitro fertilization (IVF). MATERIALS AND METHODS This prospective randomized controlled trial included a total...

Ovarian hyperstimulation syndrome (OHSS) was first described in 1960. It may occur as a complication of gonadotropin hormone therapy during assisted pregnancy or for primary infertility. A 26-year-old female patient with polycystic ovarian syndrome and primary infertility was treated to conceive. She received intravenous gonadotropin-releasing hormone (GnRH) along with follicle-stimulating horm...